appstore
Первая пятница декабря
nidek
Конгресс
vgogh_post
Mobile
Конгресс 2014
профессор
YouTube
cophyaa
varthamana2
eye5
Шахматы
Флаги
medlab
glaucoma_net_ru
obfsummit
oftalmolog_club
Beaver
bannerparasol
santen
facebook
askin_heid
Торика
АйНьюс.РФ
cophyeu
ВК
www.worldglaucoma.org
Главная / Новости

Новости


1 2 3 4 5 6 7 8 9 10


29 июля 2018 - Biosimilars for bevacizumab and ranibizumab show promise for retinal diseases
VANCOUVER, British Columbia — Data for two new biosimilars for ranibizumab and bevacizumab, currently available in India, show the treatments are safe and effective for a variety of retinal diseases, according to a speaker here. “Our data confirms that both these biosimilars are effective and safe. These could become the new safe, low-cost therapies for retinal diseases in the future,” Alay S. Banker, MD, said at the American Society of Retina Specialists annual meeting. The prospective, consecutive case series included 22,276 eyes that received Razumab (Intas Pharmaceutical), a biosimilar to ranibizumab (Lucentis, Genentech), and 2,237 eyes that received Zybev (Cadila Healthcare), a biosimilar to bevacizumab (Avastin, Genentech). Patients in the study were treated for a variety of retinal vascular diseases, including choroidal neovascularization secondary to age-related macular degeneration, retinal vein occlusion and diabetic macular edema. At 3-month follow-up, the mean logMAR vision of 0.72 at baseline for patients in the Razumab group experienced a statistically significant improvement to 0.54 (P < .05). The baseline central macular thickness of 406.15 µm improved to 314.1 µm, Banker said. Patients in the Zybev group experienced a statistically significant improvement in logMAR vision of 0.68 at baseline to 0.56 at 3 months (P < .05), Banker said. Eleven eyes in the Razumab group and four eyes in the Zybev group experienced intraocular inflammation, but no serious ocular or systemic adverse events were reported. – by Robert Linnehan

27 июля 2018 - Exfoliation Syndrome: A Historical Perspective
The discoverer of exfoliation was John Lindberg of Helsinki, Finland. He conducted his research as a young ophthalmology resident with the aim of elucidating 2 types of age-related degenerations of the iris and presenting it as an academic thesis. To this end, he had to construct a slit lamp, because they were not commercially available. During this investigation, he paid attention to greyish flakes and fringes on the anterior lens capsule and the pupillary border, which had not been previously described. His material consisted of 202 patients. The findings were recorded by time-consuming skillful drawings. His conclusions that the condition was age-related and often linked to chronic glaucoma and cataract are still valid today. The work was accepted as an academic thesis at the University of Helsinki in 1917.

26 июля 2018 - Clinical outcomes following trifocal diffractive intraocular lens implantation for age-related cataract in China
Purpose: The aim of this study was to evaluate visual, refractive and patient satisfaction outcomes following implantation of a trifocal diffractive intraocular lens (IOL). Patients and methods: This prospective, consecutive study included patients undergoing lens phacoemulsification of cataract and implantation of a trifocal diffractive IOL (AT LISA tri 839MP). Visual outcomes, including near, intermediate and distance visual acuity (VA), refractive error, contrast sensitivity, defocus curve and patient satisfaction were assessed preoperatively and postoperatively. Results: Thirty IOLs were implanted in 26 patients. Distance VA improved significantly from 0.70±0.45 to 0.08±0.11 logMAR (p<0.0001) 1 week postoperatively, and to 0.07±0.13 logMAR (p<0.0001) at 1 month and 0.05±0.10 logMAR (p<0.0001) at 3 months. Uncorrected near and intermediate VA, as well as corrected near, intermediate and distance VA, were stable and maintained during the follow-up period. Preoperative anterior chamber depth demonstrated an association with effective adjustment of postoperative spherical equivalent using a regression formula (p=0.007). No significant differences were observed for VA at defocus curves of 0 to -3 D. Contrast sensitivity at each spatial frequency improved significantly at 1 week, 1 month and 3 months under photopic and photopic with glare conditions. Under mesopic and mesopic with glare conditions, significant differences were observed postoperatively at low and medium spatial frequencies. Patients reported a high level of satisfaction and an absence of glare or halo 3 months postoperatively. Conclusion: In this study, the trifocal diffractive IOL provided excellent visual performance at all distances and improved contrast sensitivity under different conditions, resulting in high levels of patient satisfaction and spectacle independence in Chinese patients.

21 июля 2018 - Fighting Glaucoma: An Action Handbook
The long term challenges faced by people with glaucoma are numerous and important. With such a diagnosis, you have to balance many life demands, of which eye treatments are essential but by no means alone. After all, you are not living to treat glaucoma: you are living a full life into which the treatment of your condition is an intrusion

19 июля 2018 - Heidelberg Engineering prepares leadership team for the future
Heidelberg, Germany – Heidelberg Engineering GmbH announced today changes to the leadership team responsible to consistently deliver the company’s brand promise of excellence and innovation, supported by knowledge and confidence

14 июля 2018 - Advances in Filtering Surgery
his prospective, noncomparative, multicenter study was designed to evaluate the safety and efficacy of an ab interno gelatin stent (Xen Gel Stent, Allergan). Sixty-five patients aged 45 years or older with refractory open-angle glaucoma (OAG) and a history of failed filtering or cilioablative surgery and/or uncontrolled IOP (≥ 20 and ≤ 35 mm Hg) on maximum tolerated medical therapy were enrolled. The study protocol required a conjunctival peritomy to allow direct sponge application of 0.2 mg/mL mitomycin C (MMC) to the scleral bed for 2 minutes. The gelatin stent was then implanted in the sub-Tenon space in an ab interno fashion via a clear corneal incision under gonioscopic guidance, after which the conjunctiva was closed

13 июля 2018 - Icare® rebound tonometers: review of their characteristics and ease of use
Abstract: The rebound tonometer has a unique mechanism for measuring intraocular pressure (IOP) and has become popular worldwide due to its ease of use. The most notable advantages are the lack of an air-puff and need for topical anesthesia, ease of operation and transport, and the ability to use it with children. Four rebound tonometers (Icare® TA01i, Icare PRO, Icare HOME, and Icare ic100) are currently available for clinical examination. It is important to understand the characteristics of each tonometer and select the most appropriate one because the IOP values and the purpose of measurement are different. In this review, with the goal of improving the understanding of a range of tonometers, the issues with each device are discussed.

10 июля 2018 - Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
Abstract Purpose: Rho-associated protein kinase (ROCK) inhibitors lower intraocular pressure (IOP) by increasing aqueous outflow through the trabecular meshwork (TM). The preclinical characterization of netarsudil, a new ROCK/norepinephrine transporter (NET) inhibitor currently in clinical development, is presented herein.

09 июля 2018 - Would you like to actively participate in the World Glaucoma Congress in Melbourne?
This is your chance to submit your abstract and have it reviewed within 2 weeks after submission. A new concept to be introduced at WGC-2019: Express Abstract Review.

05 июля 2018 - Big data and glaucoma
The WGA aspires in becoming the most important source of education for ophthalmologists and other healthcare providers related to glaucoma. In becoming a knowledge platform, the association offers access to the Educational Portal that includes recorded sessions from past WGC’s.

03 июля 2018 - Ocular Therapeutix resubmits new drug application for Dextenza
Ocular Therapeutix has resubmitted a new drug application to the FDA for its ocular pain treatment Dextenza, the company announced in a press release. Dextenza (dexamethasone insert 0.4 mg) is a corticosteroid intracanalicular insert placed through the punctum to deliver dexamethasone for up to 30 days.

26 июня 2018 - MultiColor shines at ARVO in comparisons to color fundus photography
A number of international studies evaluating the sensitivity of SPECTRALIS® MultiColor confocal scanning laser ophthalmoscopy versus color fundus photography were presented at the Association for Vision and Research in Ophthalmology (ARVO) 2018 conference in Honolulu, Hawaii. The studies presented at ARVO reported better sensitivity and visualization of a number of pathologies using the SPECTRALIS MultiColor Module in comparison to color fundus photography. In the figure below Amit Meshi, UCSD, San Diego, California, USA, et al. compared retinal pathology visualization and detection between the three technologies: SPECTRALIS MultiColor Module (image B), Optos P200 (image C) and Topcon TRC-50DX (image A). The authors concluded that whilst overall detection rate of retinal pathology was similar across all three devices, a larger area of macular involvement and significantly better epiretinal membrane (ERM) visualization was noted in the SPECTRALIS.

23 июня 2018 - Preserving the Ocular Surface: Practice Pearls Part 3
Dry eye symptoms are experienced by many patients, especially with aging. Unfortunately, millions of patients with ocular surface disease are underdiagnosed in the United States. Being able to detect and treat dry eye disease in its early stages is becoming increasingly important. This CME activity will discuss the etiology, pathophysiology, and new methods of diagnosis and treatment for ocular surface disorders, as well as discuss clinical cases.

13 июня 2018 - Argus II retinal prosthesis system: a review of patient selection criteria, surgical considerations, and post-operative outcomes
Abstract: Retinitis pigmentosa (RP) is a group of heterogeneous inherited retinal degenerative disorders characterized by progressive rod and cone dysfunction and ensuing photoreceptor loss. Many patients suffer from legal blindness by their 40s or 50s. Artificial vision is considered once patients have lost all vision to the point of bare light perception or no light perception. The Argus II retinal prosthesis system is one such artificial vision device approved for patients with RP. This review focuses on the factors important for patient selection. Careful pre-operative screening, counseling, and management of patient expectations are critical for the successful implantation and visual rehabilitation of patients with the Argus II device.

12 июня 2018 - Are you attending WOC2018 in Barcelona? Be sure to join the WGA Symposium Glaucoma: Clinical Features and Progression on Tuesday.
Are you attending WOC2018 in Barcelona? Be sure to join the WGA Symposium Glaucoma: Clinical Features and Progression on Tuesday. We look forward to meeting you there

11 июня 2018 - Journal Article Review – Use of MultiColor imaging in the assessment of suspected papilledema in 20 consecutive children
True papilledema or pseudopapilledema? Differentiating between these entities in children based on noninvasive imaging would be greatly preferable over an invasive neurological examination – the current gold standard. The authors of a recent study investigated whether the SPECTRALIS® MultiColor Module is helpful to make this distinction. Taking MultiColor images from the optic nerve head of 20 consecutive patients delivered very promising results.

10 июня 2018 - Пора полистать "свежий" выпуск International Glaucoma Review
Dr. Robert N. Weinreb Chief Editor I welcome you to the International Glaucoma Review (IGR) online. As usual, the IGR will provide you with high quality glaucoma content including the Comments in the Editor’s Selection, the Dialogue, Opinion, and news from the WGA, meeting reports, etc. With this new format, you will be able to quickly navigate the content online and obtain the information that is of interest. If desired, you also will be able to obtain more details via direct links (articles, abstracts, database, etc.).

08 июня 2018 - A truly comprehensive Ophthalmology meeting, delivering a world class scientific programme
With plans well underway for SOE2019 we are pleased to share our confirmed Key note Lectures which cover the breadth of Ophthalmology and are just some of the jewels in our treasure chest that is our Scientific programme. We look forward to welcoming you to the next European Congress of Ophthalmology in Nice from 13–16 June 2019. Along with a selection of the best lecturers in the world who will share every conceivable aspect of ophthalmology, our YO Committee will provide specific YO activities and sessions and the most recent state-of-art equipment and devices will be on display at the exhibition. We look forward to seeing you in Nice in 2019! Jan Tjeerd de Faber SOE President

07 июня 2018 - Хотите увидеть много фото с конгресса во Флоренции?
Отличные фото с отличного конгресса Европейского глаукомного общества!

06 июня 2018 - Отличные презентации по разным темам глаукомы (представленные на Всемирном глаукомой конгрессе в 2017 году)
The WGA aspires in becoming the most important source of education for ophthalmologists and other healthcare providers related to glaucoma. In becoming a knowledge platform, the association offers access to the Educational Portal that includes recorded sessions from past WGC’s. Click below to watch the recorded sessions of our past Congresses. WGC-2013 and WGC-2015 content is available for all. The sessions recorded during the 7th WGC will only be available for registered participants and will be released on a monthly basis via the different WGA media channels. WGC-2017 content is only available to WGC-2017 attendees. WGA will share several WGC-2017 sessions the upcoming year via WGA media channels. Do not miss out and subscribe to the WGA newsletter!


1 2 3 4 5 6 7 8 9 10
Голосование
Что "заставляет" Вас заниматься научными исследованиями?